Ricard Ferrer

臨床医学

Clinical Medicine

Destaca también en

Immunology

HOSPITAL UNIVERSITARIO VALL D'HEBRON

Barcelona / Spain

226_th Global

¡Consigue tu badge!

Mentions data

Menciones por sus áreas de investigación

Clinical Medicine

Twitter
5K
Wikipedia
4
News
107
Policy
1

Immunology

Twitter
367
Wikipedia
0
News
68
Policy
3

Trabajos con más influratio

Clinical Medicine

Todos sus trabajos en el área Clinical Medicine

Mentions 2131 Twitter 3 Wikipedia 42 News 0 Policy

Review The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity Osuchowski, Marcin F.; Winkler, Martin S.; Skirecki, Tomasz; Cajander, Sara; Shankar-Hari, Manu; Lachmann, Gunnar; Monneret, Guillaume; Venet, Fabienne; Bauer, Michael; Brunkhorst, Frank M.; Weis, Sebastian; Garcia-Salido, Alberto; Kox, Matthijs; Cavaillon LANCET RESPIRATORY MEDICINE 2213-2600 (2021) DOI / 10.1016/s2213-2600(21)00218-6 OPEN ACCESS LEVEL / Bronze, Green published

Mentions 810 Twitter 0 Wikipedia 3 News 0 Policy

Letter Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome Chiscano-Camon, Luis; Ruiz-Rodriguez, Juan Carlos; Ruiz-Sanmartin, Adolf; Roca, Oriol; Ferrer, Ricard CRITICAL CARE 1364-8535 (2020) DOI / 10.1186/s13054-020-03249-y OPEN ACCESS LEVEL / Gold DOAJ, Green published

Immunology

Todos sus trabajos en el área Immunology

Mentions 37 Twitter 0 Wikipedia 43 News 0 Policy

Article Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients Martin-Vicente, Maria; Almansa, Raquel; Martinez, Isidoro; Tedim, Ana P.; Bustamante, Elena; Tamayo, Luis; Aldecoa, Cesar; Manuel Gomez, Jose; Renedo, Gloria; Angel Berezo, Jose; Antonio Cedeno, Jamil; Mamolar, Nuria; Garcia Olivares, Pablo; Herran-Monge, JOURNAL OF INTERNAL MEDICINE 0954-6820 (2021) DOI / 10.1111/joim.13386 OPEN ACCESS LEVEL / Bronze

Mentions 138 Twitter 0 Wikipedia 25 News 3 Policy

Article Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Bassetti, Matteo; Echols, Roger; Matsunaga, Yuko; Ariyasu, Mari; Doi, Yohei; Ferrer, Ricard; Lodise, Thomas P.; Naas, Thierry; Niki, Yoshihito; Paterson, David L.; Portsmouth, Simon; Torre-Cisneros, Julian; Toyoizumi, Kiichiro; Wunderink, Richard G.; Nagat LANCET INFECTIOUS DISEASES 1473-3099 (2021) DOI / 10.1016/s1473-3099(20)30796-9 OPEN ACCESS LEVEL /